Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK)
HKD 18.04
(0.33%)
HKD 18.04
(0.33%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 5.12 Billion CNY | 0.92% |
| 2022 | 5.07 Billion CNY | 6.02% |
| 2021 | 4.78 Billion CNY | 30.32% |
| 2020 | 3.67 Billion CNY | -9.44% |
| 2019 | 4.05 Billion CNY | 5.71% |
| 2018 | 3.83 Billion CNY | 55.87% |
| 2017 | 2.46 Billion CNY | 67.8% |
| 2016 | 1.46 Billion CNY | 3.99% |
| 2015 | 1.41 Billion CNY | 3.49% |
| 2014 | 1.36 Billion CNY | 21.67% |
| 2013 | 1.12 Billion CNY | 155.68% |
| 2012 | 438.07 Million CNY | 41.8% |
| 2011 | 308.92 Million CNY | 3.66% |
| 2010 | 298.01 Million CNY | 43.92% |
| 2009 | 207.07 Million CNY | 17.63% |
| 2008 | 176.04 Million CNY | -61.81% |
| 2007 | 460.95 Million CNY | 23.3% |
| 2006 | 373.85 Million CNY | 24.52% |
| 2005 | 300.25 Million CNY | 68.03% |
| 2004 | 178.68 Million CNY | -40.19% |
| 2003 | 298.77 Million CNY | -4.76% |
| 2002 | 313.71 Million CNY | 19.93% |
| 2001 | 261.58 Million CNY | 30.64% |
| 2000 | 200.23 Million CNY | 22.39% |
| 1999 | 163.6 Million CNY | 7.94% |
| 1998 | 151.57 Million CNY | 3.78% |
| 1997 | 146.05 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 774.97 Million CNY | 0.15% |
| 2024 Q2 | 773.84 Million CNY | -68.44% |
| 2024 Q1 | 2.45 Billion CNY | 572.52% |
| 2023 FY | 5.12 Billion CNY | 0.92% |
| 2023 Q2 | 1.18 Billion CNY | -49.82% |
| 2023 Q3 | 1.22 Billion CNY | 3.6% |
| 2023 Q1 | 2.35 Billion CNY | 283.74% |
| 2023 Q4 | 364.63 Million CNY | -70.18% |
| 2022 Q4 | 613.1 Million CNY | -45.71% |
| 2022 Q2 | 1.06 Billion CNY | -52.75% |
| 2022 Q1 | 2.26 Billion CNY | 332.14% |
| 2022 FY | 5.07 Billion CNY | 6.02% |
| 2022 Q3 | 1.12 Billion CNY | 5.62% |
| 2021 Q2 | 1.2 Billion CNY | -40.73% |
| 2021 Q1 | 2.03 Billion CNY | 839.49% |
| 2021 Q4 | 523.62 Million CNY | -48.52% |
| 2021 Q3 | 1.01 Billion CNY | -15.77% |
| 2021 FY | 4.78 Billion CNY | 30.32% |
| 2020 FY | 3.67 Billion CNY | -9.44% |
| 2020 Q3 | 1.19 Billion CNY | 60.97% |
| 2020 Q4 | 216.88 Million CNY | -81.87% |
| 2020 Q1 | 1.51 Billion CNY | 1641.73% |
| 2020 Q2 | 743.19 Million CNY | -50.98% |
| 2019 Q2 | 1.4 Billion CNY | -20.5% |
| 2019 FY | 4.05 Billion CNY | 5.71% |
| 2019 Q1 | 1.76 Billion CNY | 6250.33% |
| 2019 Q3 | 791.15 Million CNY | -43.77% |
| 2019 Q4 | 87.04 Million CNY | -89.0% |
| 2018 Q2 | 1.85 Billion CNY | 64.78% |
| 2018 Q4 | 27.86 Million CNY | -96.62% |
| 2018 FY | 3.83 Billion CNY | 55.87% |
| 2018 Q1 | 1.12 Billion CNY | 58.5% |
| 2018 Q3 | 825.74 Million CNY | -55.51% |
| 2017 Q3 | 387.84 Million CNY | -51.45% |
| 2017 FY | 2.46 Billion CNY | 67.8% |
| 2017 Q4 | 710.62 Million CNY | 83.22% |
| 2017 Q2 | 798.86 Million CNY | 41.74% |
| 2017 Q1 | 563.62 Million CNY | 55.67% |
| 2016 FY | 1.46 Billion CNY | 3.99% |
| 2016 Q1 | 493.58 Million CNY | 131.03% |
| 2016 Q2 | 392.08 Million CNY | -20.56% |
| 2016 Q3 | 218.89 Million CNY | -44.17% |
| 2016 Q4 | 362.06 Million CNY | 65.41% |
| 2015 Q2 | 503.28 Million CNY | 10.79% |
| 2015 FY | 1.41 Billion CNY | 3.49% |
| 2015 Q1 | 454.26 Million CNY | 57.93% |
| 2015 Q4 | 213.64 Million CNY | -11.53% |
| 2015 Q3 | 241.48 Million CNY | -52.02% |
| 2014 Q1 | 409.15 Million CNY | 50.67% |
| 2014 Q3 | 235.18 Million CNY | -45.41% |
| 2014 Q2 | 430.85 Million CNY | 5.3% |
| 2014 FY | 1.36 Billion CNY | 21.67% |
| 2014 Q4 | 287.63 Million CNY | 22.3% |
| 2013 FY | 1.12 Billion CNY | 155.68% |
| 2013 Q1 | 186.11 Million CNY | 58.63% |
| 2013 Q2 | 494.65 Million CNY | 165.78% |
| 2013 Q4 | 271.55 Million CNY | 61.88% |
| 2013 Q3 | 167.75 Million CNY | -66.09% |
| 2012 Q3 | 80.26 Million CNY | -24.81% |
| 2012 Q1 | 133.72 Million CNY | 156.57% |
| 2012 FY | 438.07 Million CNY | 41.8% |
| 2012 Q4 | 117.32 Million CNY | 46.17% |
| 2012 Q2 | 106.75 Million CNY | -20.17% |
| 2011 Q2 | 96.71 Million CNY | -2.6% |
| 2011 Q3 | 60.78 Million CNY | -37.15% |
| 2011 Q4 | 52.11 Million CNY | -14.26% |
| 2011 FY | 308.92 Million CNY | 3.66% |
| 2011 Q1 | 99.29 Million CNY | 97.18% |
| 2010 Q1 | 72.07 Million CNY | 41.5% |
| 2010 Q3 | 59.67 Million CNY | -48.51% |
| 2010 FY | 298.01 Million CNY | 43.92% |
| 2010 Q4 | 50.35 Million CNY | -15.61% |
| 2010 Q2 | 115.9 Million CNY | 60.8% |
| 2009 Q1 | 39.74 Million CNY | 100.28% |
| 2009 FY | 207.07 Million CNY | 17.63% |
| 2009 Q4 | 50.93 Million CNY | 27.13% |
| 2009 Q3 | 40.06 Million CNY | -47.5% |
| 2009 Q2 | 76.32 Million CNY | 92.05% |
| 2008 FY | 176.04 Million CNY | -61.81% |
| 2008 Q4 | 19.84 Million CNY | 152.78% |
| 2008 Q3 | -37.59 Million CNY | -164.65% |
| 2008 Q1 | 152.85 Million CNY | 21.85% |
| 2008 Q2 | 58.14 Million CNY | -61.96% |
| 2007 Q3 | 83.89 Million CNY | -38.2% |
| 2007 FY | 460.95 Million CNY | 23.3% |
| 2007 Q1 | 115.86 Million CNY | 10.65% |
| 2007 Q2 | 135.75 Million CNY | 17.16% |
| 2007 Q4 | 125.44 Million CNY | 49.53% |
| 2006 Q1 | 101.19 Million CNY | 77.85% |
| 2006 Q4 | 104.71 Million CNY | 35.98% |
| 2006 FY | 373.85 Million CNY | 24.52% |
| 2006 Q3 | 77 Million CNY | -15.33% |
| 2006 Q2 | 90.94 Million CNY | -10.13% |
| 2005 Q4 | 56.9 Million CNY | -19.2% |
| 2005 Q3 | 70.42 Million CNY | -16.03% |
| 2005 Q2 | 83.86 Million CNY | -5.82% |
| 2005 Q1 | 89.05 Million CNY | 78.26% |
| 2005 FY | 300.25 Million CNY | 68.03% |
| 2004 Q3 | 33.17 Million CNY | 4.38% |
| 2004 Q1 | 63.77 Million CNY | -1.34% |
| 2004 FY | 178.68 Million CNY | -40.19% |
| 2004 Q4 | 49.95 Million CNY | 50.59% |
| 2004 Q2 | 31.78 Million CNY | -50.16% |
| 2003 Q1 | 95.56 Million CNY | 36.61% |
| 2003 Q2 | 75.89 Million CNY | -20.59% |
| 2003 Q3 | 62.67 Million CNY | -17.42% |
| 2003 FY | 298.77 Million CNY | -4.76% |
| 2003 Q4 | 64.63 Million CNY | 3.13% |
| 2002 Q1 | 91.58 Million CNY | 0.0% |
| 2002 Q4 | 69.95 Million CNY | 49.16% |
| 2002 Q3 | 46.9 Million CNY | -55.45% |
| 2002 Q2 | 105.26 Million CNY | 14.94% |
| 2002 FY | 313.71 Million CNY | 19.93% |
| 2001 FY | 261.58 Million CNY | 30.64% |
| 2000 FY | 200.23 Million CNY | 22.39% |
| 1999 FY | 163.6 Million CNY | 7.94% |
| 1998 FY | 151.57 Million CNY | 3.78% |
| 1997 FY | 146.05 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | -3480.746% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | -92.269% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 62840.709% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | -12426.655% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 9913.343% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | -14108.137% |
| Essex Bio-Technology Limited | 310.32 Million HKD | -1550.147% |
| Tongfang Kontafarma Holdings Limited | - HKD | -Infinity% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 7853.531% |
| SSY Group Limited | 1.63 Billion HKD | -212.459% |
| JBM (Healthcare) Limited | 174.2 Million HKD | -2839.581% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | -1437.225% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 57.843% |